[{"orgOrder":0,"company":"Veraxa Biotech","sponsor":"Voyager Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Merger","leadProduct":"VX-A902","moa":"HER2","graph1":"Oncology","graph2":"Discovery","graph3":"Veraxa Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veraxa Biotech \/ Voyager Acquisition Corp","highestDevelopmentStatusID":"2","companyTruncated":"Veraxa Biotech \/ Voyager Acquisition Corp"}]

Find Oncology Clinical Drug Pipeline Developments & Deals by Veraxa Biotech

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : The combined company will focus on the development of a comprehensive pipeline of next-generation cancer therapies, including novel ADC, VX-A902, and Bispecific TCE candidates.

                          Product Name : VX-A902

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          April 23, 2025

                          Lead Product(s) : VX-A902

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Voyager Acquisition Corp

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank